Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk

Xenotransplantation

Volumn 18, Issue 1, 2011, Pages 1-5

  Padler Karavani, Vered ^a   Varki, Ajit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; CYTIDINE PHOSPHATE; EPITOPE; GLYCOCONJUGATE; N ACETYLNEURAMINIC ACID; N GLYCOLOYLNEURAMINIC ACID; SIALIC ACID;

ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BIOLOGICAL THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FETAL CALF SERUM; GRAFT REJECTION; HUMAN; INTESTINE FLORA; NOTE; PRIORITY JOURNAL; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES; EPITOPES; GRAFT REJECTION; HUMANS; N-ACETYLNEURAMINIC ACID; NEURAMINIC ACIDS; RISK FACTORS;

EID: 79952016220     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2011.00622.x     Document Type: Note

References (43)

1. Galili U,. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol 2005; 83: 674-686. (Pubitemid 43083100)
2. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM,. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988; 56: 1730-1737.
3. Cooper DK, Gollackner B, Sachs DH,. Will the pig solve the transplantation backlog? Annu Rev Med 2002; 53: 133-147. (Pubitemid 34177875)
4. Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11: 29-31. (Pubitemid 40215833)
5. Miwa Y, Kobayashi T, Nagasaka T, et al. Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation? Xenotransplantation 2004; 11: 247-253. (Pubitemid 38623061)
6. Tahara H, Ide K, Basnet NB, et al. Immunological property of antibodies against N-glycolylneuraminic acid epitopes in cytidine monophospho-N- acetylneuraminic acid hydroxylase-deficient mice. J Immunol 2010; 184: 3269-3275.
7. Yeh P, Ezzelarab M, Bovin N, et al. Investigation of potential carbohydrate antigen targets for human and baboon antibodies. Xenotransplantation 2010; 17: 197-206.
8. Diswall M, Angstrom J, Karlsson H, et al. Structural characterization of alpha1,3-galactosyltransferase knockout pig heart and kidney glycolipids and their reactivity with human and baboon antibodies. Xenotransplantation 2010; 17: 48-60.
9. Yuriev E, Agostino M, Farrugia W, Christiansen D, Sandrin MS, Ramsland PA,. Structural biology of carbohydrate xenoantigens. Expert Opin Biol Ther 2009; 9: 1017-1029.
10. Varki A,. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. Proc Natl Acad Sci U S A 2010; 107 (Suppl. 2): 8939-8946.
11. Hedlund M, Tangvoranuntakul P, Takematsu H, et al. N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol Cell Biol 2007; 27: 4340-4346. (Pubitemid 46906558)
12. Tangvoranuntakul P, Gagneux P, Diaz S, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A 2003; 100: 12045-12050. (Pubitemid 37271512)
13. Bardor M, Nguyen DH, Diaz S, Varki A,. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 2005; 280: 4228-4237. (Pubitemid 40288589)
14. Nguyen DH, Tangvoranuntakul P, Varki A,. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol 2005; 175: 228-236. (Pubitemid 40884323)
15. Padler-Karavani V, Yu H, Cao H, et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008; 18: 818-830.
16. Hedlund M, Padler-Karavani V, Varki NM, Varki A,. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci U S A 2008; 105: 18936-18941.
17. Pham T, Gregg CJ, Karp F, et al. Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. Blood 2009; 114: 5225-5235.
18. Malykh YN, Schauer R, Shaw L,. N-glycolylneuraminic acid in human tumours. Biochimie 2001; 83: 623-634. (Pubitemid 32821226)
19. Noguchi A, Mukuria CJ, Suzuki E, Naiki M,. Failure of human immunoresponse to N-glycolylneuraminic acid epitope contained in recombinant human erythropoietin. Nephron 1996; 72: 599-603. (Pubitemid 26098259)
20. Martin MJ, Muotri A, Gage F, Varki A,. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005; 11: 228-232. (Pubitemid 40321360)
21. Cohen M, Varki A,. The sialome-far more than the sum of its parts. OMICS 2010; 14: 455-464.
22. Kabat EA, Nickerson KG, Liao J, et al. A human monoclonal macroglobulin with specificity for alpha(2-8)-linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA. J Exp Med 1986; 164: 642-654. (Pubitemid 16050707)
23. Wang D, Hubbard JM, Kabat EA,. Modeling study of antibody combining sites to (alpha 1-6)dextrans. Predictions of the conformational contribution of VL-CDR3 and J kappa segments to groove-type combining sites. J Biol Chem 1993; 268: 20584-20589. (Pubitemid 23278973)
24. Diaz SL, Padler-Karavani V, Ghaderi D, et al. Sensitive and specific detection of the non-human sialic acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. PLoS ONE 2009; 4: e4241.
25. Cerdan C, Bendall SC, Wang L, Stewart M, Werbowetski T, Bhatia M,. Complement targeting of nonhuman sialic acid does not mediate cell death of human embryonic stem cells. Nat Med 2006; 12: 1113-1114. (Pubitemid 44527337)
26. Martin MJ, Muotri A, Gage F, Varki A,. Response to Cerdan et al.: complement targeting of nonhuman sialic acid does not mediate cell death of human embryonic stem cells. Nat Med 2006; 12: 1115. (Pubitemid 44527338)
27. Lanctot PM, Gage FH, Varki AP,. The glycans of stem cells. Curr Opin Chem Biol 2007; 11: 373-380. (Pubitemid 47302845)
28. Reemtsma K,. Renal heterotransplantation from nonhuman primates to man. Ann N Y Acad Sci 1969; 162: 412-418.
29. Toledo-Pereyra LH, Lopez-Neblina F,. Xenotransplantation: a view to the past and an unrealized promise to the future. Exp Clin Transplant 2003; 1: 1-7.
30. Barnard CN, Cooper DK,. Clinical transplantation of the heart: a review of 13 years' personal experience. J R Soc Med 1981; 74: 670-674. (Pubitemid 12227110)
31. Vesely I,. Heart valve tissue engineering. Circ Res 2005; 97: 743-755. (Pubitemid 41447124)
32. Badylak SF, Gilbert TW,. Immune response to biologic scaffold materials. Semin Immunol 2008; 20: 109-116.
33. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A,. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 2010; 28: 863-867.
34. Heiskanen A, Satomaa T, Tiitinen S, et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007; 25: 197-202. (Pubitemid 46052991)
35. Hashii N, Kawasaki N, Nakajima Y, et al. Study on the quality control of cell therapy products. Determination of N-glycolylneuraminic acid incorporated into human cells by nano-flow liquid chromatography/Fourier transformation ion cyclotron mass spectrometry. J Chromatogr A 2007; 1160: 263-269. (Pubitemid 47068487)
36. Nystedt J, Anderson H, Hirvonen T, et al. Human CMP-N-acetylneuraminic acid hydroxylase is a novel stem cell marker linked to stem cell-specific mechanisms. Stem Cells 2010; 28: 258-267.
37. Komoda H, Okura H, Lee CM, et al. Reduction of N-glycolylneuraminic acid xenoantigen on human adipose tissue-derived stromal cells/mesenchymal stem cells leads to safer and more useful cell sources for various stem cell therapies. Tissue Eng Part A 2010; 16: 1143-1155.
38. Hayashi Y, Chan T, Warashina M, et al. Reduction of N-glycolylneuraminic acid in human induced pluripotent stem cells generated or cultured under feeder- and serum-free defined conditions. PLoS ONE 2010; 5: e14099.
39. Ezzelarab M, Cooper DK,. Reducing Gal expression on the pig organ-a retrospective review. Xenotransplantation 2005; 12: 278-285. (Pubitemid 40868329)
40. Basnet NB, Ide K, Tahara H, Tanaka Y, Ohdan H,. Deficiency of N-glycolylneuraminic acid and Galalpha1-3Galbeta1-4GlcNAc epitopes in xenogeneic cells attenuates cytotoxicity of human natural antibodies. Xenotransplantation 2010; 17: 440-448.
41. Wang TH, Chen YY, Pan HH, Wang FP, Cheng CH, Lee WC,. Production of N-acetyl-d-neuraminic acid using two sequential enzymes overexpressed as double-tagged fusion proteins. BMC Biotechnol 2009; 9: 63.
42. Milland J, Christiansen D, Lazarus BD, Taylor SG, Xing PX, Sandrin MS,. The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene. J Immunol 2006; 176: 2448-2454. (Pubitemid 43201695)
43. Christiansen D, Milland J, Mouhtouris E, et al. Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol 2008; 6: e172.